Prostate cancer: any room left for immunotherapies?

Immunotherapy. 2019 Feb;11(2):69-74. doi: 10.2217/imt-2018-0159.
No abstract available

Keywords: CD8 T cells; MHC class I; PD-1/PD-L1; endogenous immunity; immune checkpoint blockade; mutational load; prostate cancer.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, Neoplasm / genetics
  • Antigens, Neoplasm / immunology
  • B7-H1 Antigen / antagonists & inhibitors
  • Biomarkers, Tumor
  • CD8-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / transplantation
  • Cancer Vaccines / immunology*
  • Histocompatibility Antigens Class I / metabolism
  • Humans
  • Immunity
  • Immunotherapy / methods*
  • Male
  • Mutation / genetics
  • Mutation / immunology
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Prostatic Neoplasms / immunology
  • Prostatic Neoplasms / therapy*

Substances

  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • B7-H1 Antigen
  • Biomarkers, Tumor
  • Cancer Vaccines
  • Histocompatibility Antigens Class I
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor